RIPK3 and colonic neoplasm: Several previous studies demonstrated that dabrafenib actually inhibits the RIPK3-mediated phosphorylation of MLKL in vitro using human melanoma cells, human dermal fibroblasts, human colon cancer cells, and leukemia cells [30,33,53].